Biotech & Life Sciences in China Update: CDE Releases New Guidelines for Rare Disease Drug Trials in China — Key Takeaways

On September 12, 2024, the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) released the Technical Guidelines for Clinical Trials of Rare Disease Drugs (Trial), introducing significant flexibilities for developers targeting China’s 207 designated rare diseases. With an estimated 20 million Chinese patients living with rare conditions — 70% of which are genetic in origin — the guidelines aim to accelerate drug development in a market projected to reach ¥200 billion (approximately $28 billion) by 2030.

The 2024 update marks a notable departure from the CDE’s 2021 draft, which required at least 100 patients per trial arm for pivotal studies. The new framework explicitly permits single-arm trials, external control arms, and Bayesian statistical methods when patient populations fall below 50. For foreign biotech firms eyeing the 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) pathway, the shift lowers both the time and cost barriers that historically made rare disease development in China a non-starter compared to the U.S. FDA or EMA.

This article breaks down what the guidelines actually change, which provisions matter most for foreign sponsors, and how to structure a China-aligned rare disease program in 2025.

Background: China’s Rare Disease Policy Evolution

China’s rare disease regulatory framework has matured rapidly. In 2018, the National Health Commission published the First List of Rare Diseases, covering 121 conditions. That list expanded to 207 diseases in September 2021, adding metabolic disorders, neuromuscular diseases, and pediatric genetic syndromes that affect fewer than 1 in 10,000 people — the official Chinese prevalence threshold for “rare.”

The 药品审评中心 (Center for Drug Evaluation, CDE, yàopǐn shěnpíng zhōngxīn) has since issued a series of rare disease-specific guidance documents. A 2022 draft on “Communication and Review for Rare Disease Drugs” established priority review and fee waivers for qualifying applications. However, the 2022 draft still defaulted to conventional randomized controlled trial (RCT) designs, which are often infeasible when global prevalence is measured in hundreds, not thousands.

The 2024 guidelines directly address this mismatch. For context, the U.S. FDA has approved over 600 orphan drug designations since 1983, while China’s CDE had greenlit only 38 rare disease drugs under its priority review pathway by the end of 2023. The gap reflects not a lack of demand — China accounts for roughly 18% of the global rare disease patient population — but a regulatory infrastructure that, until now, lacked explicit trial flexibility for ultra-rare populations.

Key Changes in the 2024 CDE Guidelines

1. Explicit Acceptance of Single-Arm and External Control Trials

The most consequential change is the CDE’s formal acceptance of single-arm trials with external or historical control arms for rare disease drugs. Previously, sponsors were expected to justify any deviation from the RCT standard on a case-by-case basis, creating uncertainty that delayed protocol submissions by 6-12 months. The 2024 guidelines state that “when patient numbers are insufficient to support a concurrent control group, single-arm trials using external control data from natural history studies or prior clinical registry data may be considered acceptable for pivotal evidence.”

For foreign biotech firms, this means a China-aligned development plan can now mirror the U.S. FDA’s approach for ultra-rare diseases. A company running a single-arm Phase II/III study for a condition with, say, 80 known patients globally can include Chinese sites without needing to double the sample size or run a separate RCT in China.

2. Bayesian and Adaptive Design Flexibility

The guidelines explicitly endorse Bayesian statistical methods and adaptive trial designs — including dose-finding, seamless Phase II/III, and sample-size re-estimation — for rare disease drug development. This is a notable shift from the CDE’s historical preference for frequentist statistics with fixed sample sizes. The guidance provides technical appendices on prior distribution selection and sensitivity analysis requirements for Bayesian approaches.

In practice, this allows sponsors to generate regulatory-grade evidence with smaller sample sizes. For example, a drug targeting a rare disease with a 15% spontaneous remission rate might need 80 patients per arm under a frequentist design. With Bayesian borrowing of external data, the CDE states that “credible evidence may be achievable with 30-40 patients in a single-arm setting.”

3. Special Provisions for N<50 Trials

The 2024 guidelines dedicate an entire section to trials with fewer than 50 patients — a common reality for ultra-rare diseases. In such cases, the CDE waives the typical requirement for a separate pharmacokinetic (PK) study in Chinese healthy volunteers, accepting PK data from foreign populations with a bridging analysis instead. This eliminates roughly 8-12 months of preclinical work and ¥3-5 million in local study costs.

The CDE also states that for N<50 trials, "the quantity and quality of efficacy data may be supplemented by real-world evidence (RWE) from Chinese patient registries or expanded access programs." This is the first time the CDE has formally acknowledged RWE as supplemental pivotal evidence for rare disease drugs in China.

4. Pediatric Extrapolation and Long-Term Follow-Up

For rare diseases that primarily affect children — many metabolic and genetic conditions fall into this category — the guidelines permit extrapolation of efficacy data from adult studies when disease pathophysiology is similar. This aligns with the FDA’s Pediatric Study Decision Tree and reduces the need for separate pediatric trials. The guidelines also recommend at least 12 months of long-term safety follow-up post-approval, consistent with international standards.

Implications for Foreign Biotech Companies

Three operational implications stand out for foreign executives evaluating a China rare disease strategy.

First, the cost of a China-compliant development program drops meaningfully. Under the old regime, a sponsor targeting a 207-list rare disease would typically budget ¥15-25 million for local PK studies, a 100-patient Phase II, and a 200-patient Phase III. Under the 2024 guidelines, a single-arm N<50 study with Bayesian analysis and RWE supplementation could cost ¥5-10 million — a 60% reduction. Outsourced to a Chinese CRO with rare disease expertise, the median timeline from protocol draft to NDA submission shortens from 48 months to 30 months.

Second, timing of China entry matters more than ever. The CDE guidance explicitly encourages early consultation — before Phase II — and offers expedited scientific advice meetings within 60 days of request. Companies that engage the CDE during global Phase I or early Phase II can align their China plan with the global program, avoiding the costly “China-first” studies that previously forced sponsors to generate separate local data packages.

Third, the guidance creates a competitive window. China’s rare disease drug market is growing at a compound annual growth rate of 17% and is expected to reach ¥200 billion by 2030. Yet as of early 2024, only 38 rare disease drugs had been approved under the priority review pathway, leaving over 150 listed rare diseases with no approved therapy. For sponsors with drugs targeting high-unmet-need indications — such as spinal muscular atrophy, Fabry disease, or Duchenne muscular dystrophy — the new trial flexibility allows a faster path to first-in-China approval and market exclusivity.

Strategic Considerations for Foreign Executives

Regulatory Engagement Roadmap

The CDE’s scientific advice meetings are voluntary but strongly recommended. For a foreign biotech company, the process typically involves:

1. Pre-submission: Submit a briefing document in Chinese (30-50 pages) covering the global clinical data, proposed China development plan, and specific questions on trial design, statistical methods, and bridging strategy.
2. Meeting scheduling: The CDE aims to schedule within 60 working days of receipt. Priority is given to rare disease drugs with no approved therapy in China.
3. Face-to-face discussion: A 60-90 minute meeting with CDE review team. Simultaneous interpretation is available, but most foreign sponsors bring a bilingual regulatory lead.
4. Meeting minutes: The CDE issues official minutes within 30 days, which become binding for the review process.

Data Exclusivity and Market Protection

China’s 2020 Patent Law amendments and the 2022 Drug Administration Law implementation rules provide 6-year data exclusivity for new chemical entities and 3-year exclusivity for new indications. For rare disease drugs, the CDE has indicated that additional market protection may be available on a case-by-case basis, including priority examination of patent applications and accelerated trademark registration. The 2024 guidelines do not alter exclusivity rules directly, but faster approval timelines mean sponsors can trigger the exclusivity clock sooner.

Partnering vs. Going Alone

Foreign biotech firms face a classic make-vs-buy decision. The CDE’s new flexibility makes a solo approach more feasible for well-funded late-stage sponsors, especially those with existing CRO relationships in China. However, early-stage companies with limited China experience may benefit from a local partner who can navigate the CDE meeting process, manage Chinese patient registry access for RWE, and handle post-approval pharmacovigilance requirements.

If your drug has global Phase II data with a clear natural history comparator and you can allocate ¥15 million to China development, a solo approach with a specialized CRO is viable. If your drug is in Phase I and targets an ultra-rare pediatric condition with no established Chinese patient registry, partnering with a local biotech that has hospital access will reduce regulatory risk and shorten timelines by 12-18 months.

Pitfalls to Watch For

NEXT STEPS: 3 Recommendations for Foreign Biotech Executives

1. Map your indication to China’s 207-disease list. If your rare disease drug targets a condition on the list, file a pre-IND consultation request with the CDE within 60 days. Use the new single-arm trial provisions to align your China protocol with your global program. Read our CDE pre-IND consultation step-by-step guide for document templates and timelines.
2. Evaluate whether your global trial can incorporate Chinese sites without a separate China study. For N<50 indications, the CDE now accepts foreign PK data with bridging. If your global Phase II/III includes at least 15-20 Chinese patients at sites in China, you may avoid a dedicated local trial entirely. See our analysis in Rare Disease Drug Development in China: 2025 Regulatory Roadmap.
3. Secure access to a Chinese patient registry for RWE supplementation. The CDE’s RWE endorsement applies only if the registry data is auditable and includes standardized diagnostic coding. Top-tier Chinese hospitals like Peking Union Medical College Hospital and Ruijin Hospital maintain rare disease registries. Contact us at China Gateway 360 for introductions to registry operators in your therapeutic area.

— China Gateway 360 —
Remote China market entry support, built around execution.